Does age really matter? Radiotherapy in elderly patients with glioblastoma, the Munich experience

Abstract Background Glioblastoma is usually diagnosed around the age of 60–70 years. Patients older than 65 years are frequently described as “elderly”. Several trials with monotherapy have established treatment regimens that offer therapies with reduced side effects but reduced efficacy. We analyse...

Full description

Bibliographic Details
Published in:	Radiation Oncology
Main Authors:	Christoph Straube, Hagen Scherb, Jens Gempt, Stefanie Bette, Claus Zimmer, Friederike Schmidt-Graf, Jürgen Schlegel, Bernhard Meyer, Stephanie E. Combs
Format:	Article
Language:	English
Published:	BMC 2017-04-01
Subjects:	Best Supportive Care Gross Total Resection MGMT Promotor Methylation Karnofsky Performance Score MGMT Methylation
Online Access:	http://link.springer.com/article/10.1186/s13014-017-0809-9

Similar Items

Treatment patterns and outcomes for patients with newly diagnosed glioblastoma multiforme: a retrospective cohort study
by: Srinivas Annavarapu, et al.
Published: (2021-09-01)

The Potential Effect of the IDH1 Mutation and MGMT Gene Promoter Methylation on the Control of Glioblastoma-Associated Epilepsy in Patients Receiving Anti-Epileptic Agents and Chemotherapies
by: Maher KURDI, et al.
Published: (2021-09-01)

Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy
by: Shigeo Ohba, et al.
Published: (2025-01-01)

A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide
by: Rui-Chao Chai, et al.
Published: (2019-09-01)

A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]
by: David Gibson, et al.
Published: (2024-03-01)

Hypermethylation of MGMT Gene Promoter in Peripheral Blood Mononuclear Cells as a Noninvasive Biomarker for Colorectal Cancer Diagnosis
by: Sara Azhdari, et al.
Published: (2023-01-01)

Improved Pathologic response to chemoradiation in MGMT methylated locally advanced rectal cancer
by: Garrett L. Jensen, et al.
Published: (2023-09-01)

Influence of Intratumor Heterogeneity on the Predictivity of MGMT Gene Promoter Methylation Status in Glioblastoma
by: Giovanni Brigliadori, et al.
Published: (2020-10-01)

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
by: Melguizo Consolación, et al.
Published: (2012-12-01)

Prognosis prediction via histological evaluation of cellular heterogeneity in glioblastoma
by: Mari Kirishima, et al.
Published: (2024-10-01)

DNA methylation microarray analysis of adult gliomas: A pilot study at Groote Schuur Hospital
by: Brendon Price
Published: (2024-03-01)

The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma
by: Yildiz OG, et al.
Published: (2020-08-01)

MGMT epimutations and risk of incident cancer of the colon, glioblastoma multiforme, and diffuse large B cell lymphomas
by: Oleksii Nikolaienko, et al.
Published: (2025-02-01)

Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients
by: Halka Lhotska, et al.
Published: (2025-01-01)

Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights
by: Xianhao Huo, et al.
Published: (2024-09-01)

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
by: Elizabeth Smyth, et al.
Published: (2022-09-01)

The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas
by: Nazanin Majd, et al.
Published: (2020-11-01)

A Meta-analysis of Association between MGMT Gene  Promoter Methylation and Non-small Cell Lung Cancer
by: Nianzhen FANG, et al.
Published: (2014-08-01)

Deep learning classification of MGMT status of glioblastomas using multiparametric MRI with a novel domain knowledge augmented mask fusion approach
by: İlker Özgür Koska, et al.
Published: (2025-01-01)

Association between <i>MGMT</i> Enhancer Methylation and <i>MGMT</i> Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
by: Katja Zappe, et al.
Published: (2023-06-01)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
by: Ngan Nguyen, et al.
Published: (2021-09-01)

Prediction of MGMT methylation status in glioblastoma patients based on radiomics feature extracted from intratumoral and peritumoral MRI imaging
by: Wang-Sheng Chen, et al.
Published: (2025-07-01)

Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management
by: Rocío Rosas-Alonso, et al.
Published: (2024-05-01)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
by: Combs Stephanie E, et al.
Published: (2011-09-01)

Genetic Profile of Primary Brain Tumours and the Degree of Their Resection Versus Survival of Patients Undergoing Surgery and Complementary Oncological Treatment
by: Lech Grzelak, et al.
Published: (2022-12-01)

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results
by: Matthew McCord, et al.
Published: (2023-11-01)

A Multimodal Knowledge-Based Deep Learning Approach for MGMT Promoter Methylation Identification
by: Salvatore Capuozzo, et al.
Published: (2022-12-01)

Methylation of BRCA1 and MGMT genes in white blood cells are transmitted from mothers to daughters
by: Nisreen Al-Moghrabi, et al.
Published: (2018-07-01)

18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma
by: Ziren Kong, et al.
Published: (2019-08-01)

O6-MethylGuanine-DNA Methyltransferase (MGMT) Promoter Methylation Status Analysis in High-Grade Gliomas
by: Hoda Ibrahim, et al.
Published: (2021-03-01)

Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future
by: Castalia Fernández, et al.
Published: (2025-09-01)

Current chemotherapy strategies for adults with IDH-wildtype glioblastoma
by: Jing Bao, et al.
Published: (2024-07-01)

ABERRANT METHYLATION OF THE PROMOTER OF APC, CDH13 AND MGMT GENES IN COLORECTAL CANCER PATIENTS
by: O. I. Kit, et al.
Published: (2016-07-01)

A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for <i>MGMT</i> Gene Promoter Hypermethylation Detection
by: Marco Macagno, et al.
Published: (2024-11-01)

Expression and Promoter-Hyper Methylation Analysis of MGMT Gene in Patients with Pterygium
by: Reyhane Iraji, et al.
Published: (2019-04-01)

Cognitive functioning in a cohort of high-grade glioma patients
by: Skufca Smrdel Andreja Cirila, et al.
Published: (2023-06-01)

Towards a molecular classification of colorectal cancer: The role of MGMT
by: Parham eMinoo, et al.
Published: (2013-10-01)

The Impact of <i>MGMT</i> Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
by: Nikola Jovanović, et al.
Published: (2019-02-01)

Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease
by: Jodi Goldman, et al.
Published: (2022-03-01)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
by: Fatih Incekara, et al.
Published: (2020-05-01)